Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Rafael Fonseca MD Editor-in-Chief

See All Experts

story of the week

Published in Oncology

Journal Scan / Research · November 16, 2023

First-Line Selpercatinib or Chemotherapy and Pembrolizumab for RET Fusion–Positive NSCLC

The New England Journal of Medicine

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Selpercatinib for Advanced RET-Mutant Medullary Thyroid Cancer

The New England Journal of Medicine

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC

N. Engl. J. Med 2023 Oct 21;[EPub Ahead of Print], C Zhou, B Solomon, HH Loong, K Park, M Pérol, E Arriola, S Novello, B Han, J Zhou, A Ardizzoni, MP Mak, FC Santini, YY Elamin, A Drilon, J Wolf, N Payakachat, MK Uh, D Rajakumar, H Han, T Puri, V Soldatenkova, AB Lin, BK Lin, K Goto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

First-Line Selpercatinib or Chemotherapy and Pembrolizumab for RET Fusion–Positive NSCLC

Additional Info

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC

Further Reading

Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma

Neoadjuvant and Adjuvant Toripalimab for Locoregionally Advanced Nasopharyngeal Carcinoma

ASH 2024: Abstract Recommendations From Drs. Evani Patel and David Henry

ASH 2024: Abstract Recommendations From Dr. Rafael Fonseca

An Integrative Precision Medicine Approach Using Genomics and Avatar Models to Guide Treatment in Pancreatic Cancer

Disease-Free Survival as a Surrogate for Overall Survival in Esophageal Cancer in Real-World Settings

Long-Term Outcomes After Adding a Contact X-Ray Brachytherapy Boost to Standard Neoadjuvant Chemoradiotherapy for Organ Preservation in Patients With Early Rectal Adenocarcinoma

Comparison of First-Line Chemotherapy Regimens in Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Safety and Efficacy of Pembrolizumab, Radiation Therapy, and Surgery in Patients With Stage III Soft Tissue Sarcoma of the Extremity

Glutaminase Inhibition Plus Azacitidine for Myelodysplastic Syndromes

The Lancet Breast Cancer Commission: Evidence-Based Roadmap to Address Urgent Global Breast Cancer Challenges

Recently Updated